{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T19:01:38Z","timestamp":1777748498000,"version":"3.51.4"},"reference-count":42,"publisher":"SAGE Publications","issue":"3-4","license":[{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ISB"],"published-print":{"date-parts":[[2022,1,7]]},"abstract":"<jats:p>Vascular endothelial growth factor (VEGF) has been known as a key mediator of angiogenesis in cancer. Bevacizumab is anti-VEGF monoclonal antibody that has been approved by the FDA as a first-line treatment in many types of cancer. In this paper, we extend a previously validated multiscale tumor model to comprehensively include the multiple roles of VEGF during the course of angiogenesis and its binding mechanism with bevacizumab. We use the model to simulate tumor system response under various bevacizumab concentrations, both in stand-alone treatment and in combination with chemotherapy. Our simulation indicates that periodic administration of bevacizumab with lower concentration can achieve greater efficacy than a single treatment with higher concentration. The simulation of the combined therapy also shows that the continuous administration of bevacizumab during the maintenance phase can lead to antitumor activity which further suppresses its growth. Agreement with experimental results indicates the potential of the model in predicting the efficacy of anti-VEGF therapies and could therefore contribute to developing prospective clinical trials.<\/jats:p>","DOI":"10.3233\/isb-210235","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T12:43:12Z","timestamp":1640090592000},"page":"71-88","source":"Crossref","is-referenced-by-count":3,"title":["Multiscale modeling of tumor response to vascular endothelial growth factor (VEGF) inhibitor"],"prefix":"10.1177","volume":"14","author":[{"given":"Melisa","family":"Hendrata","sequence":"first","affiliation":[{"name":"Department of Mathematics, California State University, Los Angeles, CA, USA"}]},{"given":"Janti","family":"Sudiono","sequence":"additional","affiliation":[{"name":"Department of Oral Pathology, Faculty of Dentistry, Trisakti University, Jakarta, Indonesia"}]}],"member":"179","reference":[{"key":"10.3233\/ISB-210235_ref1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1083\/jcb.200302047","article-title":"VEGF guidesangiogenic sprouting utilizing endothelial tip cell filopodia","volume":"161","author":"Gerhardt","year":"2003","journal-title":"Journal of Cell Biology"},{"issue":"1996","key":"10.3233\/ISB-210235_ref2","first-page":"57","article-title":"Differential endothelialmigration and proliferation to basic fibroblast growth factor andvascular endothelial growth factor","volume":"13","author":"Yoshida","journal-title":"Growth Factors"},{"key":"10.3233\/ISB-210235_ref3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1040-8428(89)80002-2","article-title":"Tumor-related angiogenesis","volume":"9","author":"Paweletz","year":"1989","journal-title":"Critical Review in Oncology\/Hematology"},{"key":"10.3233\/ISB-210235_ref4","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1083\/jcb.101.6.2330","article-title":"Human endothelialcells are chemotactic to endothelial cell growth factor and heparin","volume":"101","author":"Terranova","year":"1985","journal-title":"Journal of Cell Biology"},{"key":"10.3233\/ISB-210235_ref5","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cell.2009.05.024","article-title":"Jagged gives endothelial tip cells anedge","volume":"137","author":"Suchting","year":"2009","journal-title":"Cell"},{"key":"10.3233\/ISB-210235_ref6","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1074\/jbc.271.6.3154","article-title":"Heterodimers of placenta growthfactor\/vascular endothelial growth factor: endothelial activity,tumor cell expression, and high affinity binding to FLK-1\/KDR","volume":"271","author":"Cao","year":"1996","journal-title":"Journal of Biological Chemistry"},{"key":"10.3233\/ISB-210235_ref7","first-page":"1237","article-title":"Matrix metalloproteinases in angiogenesis: amoving target for therapeutic intervention","volume":"103","author":"Stetler-Stevenson","year":"1999","journal-title":"Journal of ClinicalInvestigation"},{"key":"10.3233\/ISB-210235_ref8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0022-5193(05)80201-2","article-title":"Analysis of the roles ofmicrovessel endothelial cell random motility and chemotaxis inangiogenesis","volume":"152","author":"Stokes","year":"1991","journal-title":"Journal of Theoretical Biology"},{"key":"10.3233\/ISB-210235_ref9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.cell.2007.06.054","article-title":"Autocrine VEGF signaling isrequired for vascular homeostatis","volume":"130","author":"Lee","year":"2007","journal-title":"Cell"},{"key":"10.3233\/ISB-210235_ref10","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1042\/bst0311171","article-title":"VEGF signaling: integration and multi-tasking inendothelial cell biology","volume":"31","author":"Zachary","year":"2003","journal-title":"Biochem Soc Trans"},{"key":"10.3233\/ISB-210235_ref11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0002-9440(10)65284-4","article-title":"Vascular endothelial growth factor (VEGF)-mediated angiogenesis isassociated with enhanced endothelial cell survival and induction ofBcl-2 expression","volume":"154","author":"N\u00f6r","year":"1999","journal-title":"Am J Pathol"},{"key":"10.3233\/ISB-210235_ref12","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5985031"},{"key":"10.3233\/ISB-210235_ref13","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jtbi.2009.06.026","article-title":"A pharmacologically based multiscale mathematicalmodel of angiogenesis and its use in investigating the efficacy of anew cancer treatment strategy","volume":"260","author":"Billy","year":"2009","journal-title":"Journal of Theoretical Biology"},{"key":"10.3233\/ISB-210235_ref14","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/830515"},{"key":"10.3233\/ISB-210235_ref15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1742-4682-10-41","article-title":"Multi-scale agent-based modeling on melanoma andits related angiogenesis analysis","volume":"10","author":"Wang","year":"2013","journal-title":"Theor Biol Med Model"},{"key":"10.3233\/ISB-210235_ref16","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/1471-2105-13-218","article-title":"Multi-scale agent-based braincancer modeling and prediction of TKI treatment response: Incorporating EGFR signaling pathway and angiogenesis","volume":"13","author":"Sun","year":"2012","journal-title":"BMC Bioinformatics"},{"key":"10.3233\/ISB-210235_ref17","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jtbi.2018.11.018","article-title":"Mathematical modeling in scheduling cancertreatment with combination of VEGF inhibitor and chemotherapy drugs","volume":"462","author":"Lai","year":"2019","journal-title":"J Theor Biol"},{"key":"10.3233\/ISB-210235_ref18","doi-asserted-by":"crossref","first-page":"23087","DOI":"10.18632\/oncotarget.15484","article-title":"Model driven optimization of antiangiogenics +cytotoxics combination: application to breast cancer mice treatedwith bevacizumab + paclitaxel doublet leads to reduced tumor growthand fewer metastasis","volume":"8","author":"Mollard","year":"2017","journal-title":"Oncotarget"},{"issue":"2009","key":"10.3233\/ISB-210235_ref19","first-page":"2926","article-title":"Quantification ofendothelial cell-targeted anti-BCl-2 therapy and its suppression oftumor growth and vascularization","volume":"8","author":"Jain","journal-title":"Mol Cancer Ther"},{"key":"10.3233\/ISB-210235_ref20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11538-007-9242-9","article-title":"Modeling theVEGF-Bcl-2-CXCL8 pathway in intratumoral angiogenesis","volume":"70","author":"Jain","year":"2008","journal-title":"Bull Math Bio"},{"key":"10.3233\/ISB-210235_ref21","first-page":"187","article-title":"Computational systems biologyapproaches to antiangiogenic cancer therapeutics","volume":"20","author":"Finley","year":"2015","journal-title":"Drug DiscovToday"},{"key":"10.3233\/ISB-210235_ref22","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4910603"},{"key":"10.3233\/ISB-210235_ref23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/ISB-170469","article-title":"A hybrid multiscale model forinvestigating tumor angiogenesis and its response to cell-basedtherapy","volume":"13","author":"Hendrata","year":"2019","journal-title":"In Silico Biology"},{"key":"10.3233\/ISB-210235_ref24","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3892\/etm.2014.1991","article-title":"Effect of Avastinon the number and structure of tumor blood vessels of nude mice withA549 lung adenocarcinoma","volume":"8","author":"Zhang","year":"2014","journal-title":"Experimental and TherapeuticMedicine"},{"key":"10.3233\/ISB-210235_ref27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/sj.onc.1204062","article-title":"Taxol-induced apoptosis depends on MAP kinasepathways (ERK and p38) and is independent of p53","volume":"20","author":"Bacus","year":"2001","journal-title":"Oncogene"},{"key":"10.3233\/ISB-210235_ref29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jsps.2016.07.002","article-title":"An overview of pharmacodynamicmodelling, ligand-binding approach and its application in clinicalpractice","volume":"25","author":"Salahudeen","year":"2017","journal-title":"Saudi Pharm J"},{"key":"10.3233\/ISB-210235_ref30","doi-asserted-by":"crossref","first-page":"16349","DOI":"10.1074\/jbc.274.23.16349","article-title":"Akt mediates cytoprotection of endothelialcells by vascular endothelial growth factor in ananchorage-dependent manner","volume":"274","author":"Fujio","year":"1999","journal-title":"J Biol Chem"},{"key":"10.3233\/ISB-210235_ref31","doi-asserted-by":"crossref","first-page":"30336","DOI":"10.1074\/jbc.273.46.30336","article-title":"Vascular endothelial growth factor regulatesendothelial cell survival through the phosphatidylinositol3-kinase\/Akt signal transduction pathway: requirement for Flk-1\/KDRactivation","volume":"273","author":"Gerber","year":"1998","journal-title":"J Biol Chem"},{"key":"10.3233\/ISB-210235_ref32","doi-asserted-by":"crossref","first-page":"13313","DOI":"10.1074\/jbc.273.21.13313","article-title":"Vascular endothelial growthfactor induces expression of the antiapoptotic proteins Bcl-2 and A1in vascular endothelial cells","volume":"273","author":"Gerber","year":"1998","journal-title":"J Biol Chem"},{"key":"10.3233\/ISB-210235_ref33","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1006\/jmcc.1996.0365","article-title":"Vascular endothelial growth factorinhibits endothelial cell apoptosis induced by tumor necrosisfactor-alpha: balance between growth and death signals","volume":"29","author":"Spyridopoulos","year":"1997","journal-title":"J MolCell Cardiol"},{"issue":"2001","key":"10.3233\/ISB-210235_ref34","first-page":"273","article-title":"and D.J.Bouchier-Hayes, Vascular endothelial growth factor (VEGF)upregulates BCl-2 and inhibits apoptosis in human and murine mammaryadenocarcinoma cells","volume":"85","author":"Pidgeon","journal-title":"British Journal of Cancer"},{"key":"10.3233\/ISB-210235_ref35","first-page":"699","article-title":"Tumor-inducedneovascularization in the mouse eye","volume":"69","author":"Muthukkaruppan","year":"1982","journal-title":"J Natl Cancer Inst"},{"key":"10.3233\/ISB-210235_ref36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.21705\/mcbs.v2i1.18","article-title":"Angiogenesis intensity within benign andmalignant oral mucosa epithelial tumor","volume":"2","author":"Sudiono","year":"2018","journal-title":"Mol Cell Biomed Sci"},{"key":"10.3233\/ISB-210235_ref37","doi-asserted-by":"crossref","first-page":"623","DOI":"10.21873\/anticanres.11356","article-title":"Importance of bevacizumab maintenance followingcombination chemotherapy in human non-small cell lung cancerxenograft models","volume":"37","author":"Ishikura","year":"2017","journal-title":"Anticancer Research"},{"key":"10.3233\/ISB-210235_ref38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/BF00582204","article-title":"Oxygen diffusivity in tumortissue (DS-Carcinosarcoma) under temperature conditions within therange of 20-40C","volume":"372","author":"Grote","year":"1977","journal-title":"Pugers Archiv"},{"key":"10.3233\/ISB-210235_ref39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2184.1992.tb01433.x","article-title":"Mathematicalmodelling of microenvironment and growth in EMT6\/Ro multicellulartumor spheroids","volume":"25","author":"Casciari","year":"1992","journal-title":"Cell Proliferation"},{"key":"10.3233\/ISB-210235_ref40","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1083\/jcb.149.6.1309","article-title":"Regulation of cell invasion and morphogenesis in a 3-dimensionaltype I collagen matrix by membrane-type metalloproteinases 1, 2 and 3","volume":"149","author":"Hotary","year":"2000","journal-title":"Journal of Cell Biology"},{"key":"10.3233\/ISB-210235_ref41","first-page":"163","article-title":"A hybrid mathematical model of solid tumourinvasion: the importance of cell adhesion","volume":"22","author":"Anderson","year":"2005","journal-title":"MathematicalMedicine and Biology"},{"key":"10.3233\/ISB-210235_ref42","first-page":"857","article-title":"Continuous and Discrete MathematicalModels of Tumor-induced Angiogenesis","volume":"60","author":"Anderson","year":"1998","journal-title":"Bulletin of MathematicalBiology"},{"key":"10.3233\/ISB-210235_ref43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascularendothelial growth factor (VEGF) and related ligands by VEGF Trap,ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"issue":"8","key":"10.3233\/ISB-210235_ref44","doi-asserted-by":"publisher","first-page":"e70395","DOI":"10.1371\/journal.pone.0070395","article-title":"Interstitial Fluid Flow and Drug Deliveryin Vascularized Tumors: A Computational Model","volume":"8","author":"Welter","year":"2013","journal-title":"PLoS ONE"},{"key":"10.3233\/ISB-210235_ref45","first-page":"33","article-title":"Estimation of partition, free and specificdiffusion coefficients of paclitaxel and taxanes in a fixed bed bymoment analysis: experimental, modeling and simulation studies","volume":"34","author":"Cremasco","year":"2012","journal-title":"Acta Scientiarum"}],"container-title":["In Silico Biology"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/ISB-210235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:49:26Z","timestamp":1777463366000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/ISB-210235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":42,"journal-issue":{"issue":"3-4"},"URL":"https:\/\/doi.org\/10.3233\/isb-210235","relation":{},"ISSN":["1386-6338","1434-3207"],"issn-type":[{"value":"1386-6338","type":"print"},{"value":"1434-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,7]]}}}